We develop heart-targeted LNPs through cardiotropic lipid engineering and cardiac cell-targeting surface functionalization, providing end-to-end support from lipid design and synthesis to formulation, characterization, and delivery evaluation.
Heart-targeted LNPs are engineered to deliver nucleic acids and other payloads to cardiomyocytes, cardiac fibroblasts, and cardiac endothelial cells. Unlike conventional LNPs, which distribute 30–90% of the administered dose to the liver and spleen, heart-targeted formulations use cardiotropic ionizable lipids, tailored PEG-lipid architectures, or surface-displayed targeting ligands to redirect biodistribution toward the myocardium. These systems are being investigated for mRNA expression, gene silencing, genome editing, cardiac repair, and cardiovascular disease research.
BOC Sciences provides integrated targeted LNP development, covering cardiotropic lipid screening, targeting ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo cardiac evaluation. We support the development of customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with formulation and delivery-route strategies selected according to the intended cardiac target.
Cardiac Tissue-Targeted Lipid Nanoparticle IllustrationOur development services integrate lipid chemistry, cardiac cell-targeting surface engineering, nanoparticle formulation, and biological evaluation to address the delivery barriers specific to the heart. Projects can start with an existing LNP formulation, a candidate targeting ligand, or a defined cardiac-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.
We investigate how ionizable lipid structures and supporting lipid components influence cardiac-cell interactions, intracellular delivery, and tissue distribution.
We develop ligand-functionalized LNPs to improve interactions with selected cardiac cell populations. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended cardiac-delivery application.
We evaluate the physicochemical properties of candidate LNPs alongside cardiac-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.
Heart-targeted LNPs can be developed through intrinsic lipid engineering, cardiac-homing peptide display, injury-microenvironment-responsive design, or systematic formulation optimization. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies provide different options for developing heart-targeted delivery systems.
Cardiotropic LNPs can be developed by modifying ionizable lipid headgroups, hydrophobic tails, and linker structures to shift tissue distribution away from the liver and improve uptake by cardiac cells, which are known for their low endocytic activity. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.
Research reference: 18:1 TAP10 LNPs identified through a human iPSC-derived cardiomyocyte screening platform, enabling cardiac mRNA delivery across multiple administration routes and adenine base-editor delivery with on-target correction in DMD patient-derived cardiomyocytes (PNAS, 2026).
Cardiac-homing peptides can be displayed on LNP surfaces to enhance binding to cardiomyocytes or to injured myocardium. BOC Sciences supports peptide synthesis, lipid-anchor conjugation, surface-density optimization, and LNP functionalization.
Research reference: AT1 receptor-targeted nanoparticles achieving selective delivery to the infarcted heart after intravenous injection (Biomaterials, 2011).
The injured heart presents a dynamically changing microenvironment—inflammation, oxidative stress, and fibrosis—that can be exploited for targeted delivery. BOC Sciences supports responsive lipid design, injury-stage-informed formulation, and delivery evaluation.
Research reference: High-resolution mapping showing that mRNA-LNP cell tropism in the injured heart shifts from myeloid cells at early time points toward fibroblasts, pericytes, and endothelial cells with delayed dosing (Journal of Molecular and Cellular Cardiology Plus, 2026); systemic LNPs accumulating functionally in the infarct area upon reperfusion (Journal of Controlled Release, 2022).
Cardiac delivery performance can be improved through systematic adjustment of helper lipid balance, cholesterol content, PEG-lipid architecture, and process parameters, particularly when combined with localized or catheter-based administration routes. BOC Sciences supports component-level optimization and route-adapted formulation development.
Research reference: Transcatheter intracoronary delivery of mRNA-LNPs achieving widespread myocardial expression—including cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts—and reducing infarct area with VEGF mRNA in an ischemia-reperfusion rabbit model (Journal of Controlled Release, 2025).
Share your payload and target-cell requirements. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.
BOC Sciences develops heart-targeted LNPs for the payload classes most frequently used in cardiac delivery research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect heart-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses & Heart-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Heart-Targeted LNP for mRNA | Designed for reporter expression, paracrine-factor expression, and cardiomyocyte-directed protein expression research. Development focuses on mRNA integrity, encapsulation efficiency, cardiac-cell transfection, and heart-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Heart-Targeted LNP for siRNA | Suitable for gene-knockdown studies in cardiomyocyte and cardiac fibroblast models, including pathways involved in hypertrophy, remodeling, and metabolism. Development evaluates siRNA encapsulation, target silencing in cardiac cells, and selectivity against hepatic uptake, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Heart-Targeted LNP for miRNA | Applicable to post-transcriptional regulation studies in cardiac remodeling and regeneration models. Development considers miRNA loading stability, target-cell uptake, and functional pathway readouts, supported by our lipid nanoparticles for miRNA delivery services. | Inquiry |
| Heart-Targeted LNP for Cas9 mRNA and sgRNA | Applicable to genome-editing research in cardiac models, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in cardiac cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Heart-Targeted LNP for circRNA and saRNA | Designed for payloads that require strong protection and sustained expression in cardiac tissue. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in cardiac-associated cell models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Heart-Targeted LNP for ASO | Suitable for splice-modifying and knockdown oligonucleotide research in cardiac models, where oligonucleotide delivery to cardiomyocytes remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across cardiac cell populations, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| Heart-Targeted LNP for Protein and Peptide | Applicable to enzymes, signaling proteins, and peptide payloads intended for cardiac-associated delivery research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Heart-Targeted LNP for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules studied in cardiac injury, oxidative stress, and metabolic research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs. | Inquiry |
| Heart-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map cardiac uptake, intracellular localization, and in vivo myocardial distribution trends, enabled by our fluorescent-labeled lipid nanoparticles capabilities. | Inquiry |
| Heart-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies, including multi-payload cardiac formulations. We evaluate payload compatibility, loading sequence, heart-targeting modification route, particle stability, and delivery performance in the agreed cardiac cell models, supported by our lipid nanoparticles for co-delivery capabilities. | Inquiry |
Tell us your payload, target cardiac cell population, and delivery goal, and BOC Sciences will propose a heart-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate cardiac-targeting ligand, or a defined myocardial delivery objective. We organize development into four practical stages, with formulation and biological evaluation used to guide each subsequent iteration.

We review the payload class, intended cardiac region, target cell population, administration route, and desired biological readouts. Target populations may include cardiomyocytes, cardiac fibroblasts, endothelial cells, pericytes, and cardiac-associated immune cells. We also consider whether the project focuses on healthy myocardium, ischemic tissue, or post-injury remodeling. These inputs establish the initial formulation objectives, comparator groups, and evaluation plan.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, PEG-lipid architectures, and surface modification options. The targeting layer is selected according to the intended mechanism, such as intrinsic lipid-mediated distribution, cardiac-homing peptide display, or injury-responsive chemical structures. Administration routes, including intravenous, intracoronary, and intramyocardial delivery, are evaluated according to the target region and expected tissue exposure. Lipid ratios and component combinations are screened to establish suitable candidate formulations.

Candidates are prepared using controlled mixing conditions and compared for particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload retention. During formulation optimization, we adjust lipid ratios, ligand input, PEG-lipid content, mixing conditions, purification, and buffer exchange. Where appropriate, nanoparticle intracellular localization detection can be used to investigate cellular distribution and intracellular trafficking. Candidate formulations are advanced according to predefined particle and payload performance criteria.

Selected candidates are evaluated in cardiac cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, protein production, or gene knockdown. Nanoparticle in vivo imaging services can support the investigation of heart-associated distribution, while nanoparticle in vivo distribution analysis can compare myocardial accumulation with hepatic, splenic, and other organ exposure. Findings are summarized as comparative datasets with documented formulation tradeoffs and suggested next experiments.
A heart-targeted LNP may show favorable particle characteristics yet still produce insufficient myocardial exposure or uneven delivery across cardiac cell populations. We investigate lipid composition, surface properties, administration route, and intracellular trafficking together to identify the factors limiting cardiac delivery.
✔ Hepatic Accumulation and Limited Cardiac Delivery of LNPs
Conventional LNPs frequently accumulate in the liver after systemic administration because of interactions with plasma proteins and hepatic uptake pathways. ApoE adsorption and receptor-mediated uptake are particularly relevant to this distribution pattern. We compare ionizable lipid structures, PEG-lipid content, helper lipid composition, and particle surface properties to investigate ways of improving myocardial exposure. Heart-to-liver delivery ratios are evaluated alongside absolute tissue-associated payload signals, rather than relying only on total organ fluorescence.
✔ Restricted Vascular Access and Limited Myocardial Penetration of LNPs
The cardiac microvascular endothelium, capillary architecture, and myocardial extracellular matrix can restrict nanoparticle access to deeper tissue regions. LNPs may remain within vascular compartments or show uneven distribution around local administration sites. We investigate particle size, surface charge, PEG-lipid architecture, ligand accessibility, and administration route to improve tissue exposure. Comparative imaging and tissue analysis help determine whether formulation changes improve penetration beyond the vascular or injection-site region.
✔ Uneven LNP Delivery Across Cardiac Cell Populations
Cardiomyocytes, fibroblasts, endothelial cells, pericytes, and immune cells can exhibit different uptake patterns. These patterns may also change after myocardial injury. For example, a 2026 study mapping LNP uptake after ischemia-reperfusion injury found that myeloid cells were prominent recipients during the early inflammatory phase, while fibroblast, pericyte, and endothelial cell uptake became more evident following delayed administration. We use cell-population-aware readouts, imaging, and flow cytometry to identify which cardiac cells receive the payload and whether the distribution matches the intended research objective.
✔ Limited LNP Retention and Intracellular Endosomal Escape
After local administration, LNPs may disperse rapidly from the myocardial injection site, reducing local payload exposure. Following cellular uptake, a second limitation may arise when payloads remain trapped in endosomal compartments rather than reaching their functional intracellular destination. We investigate lipid composition, acid-responsive components, particle surface properties, and local retention strategies to distinguish tissue-level loss from post-uptake delivery limitations. Where suitable, ECM-associated LNP architectures can be explored to improve local retention, while LNP endosomal escape evaluation helps identify intracellular release limitations.
Tell us about your current lipid composition, payload, administration route, and cardiac delivery results. BOC Sciences can help investigate the formulation and biological factors limiting performance and establish a focused optimization plan.
Heart-targeted LNPs offer opportunities for nucleic acid and other payload delivery in myocardial injury, cardiomyopathy, cardiac fibrosis, and tissue repair research. Different applications require different target cells and biological endpoints. BOC Sciences supports customized formulation development for these research areas, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.
Tell us your intended cardiovascular research application, target cardiac cell population, payload, and delivery requirements. BOC Sciences can help design, synthesize, formulate, and evaluate heart-targeted LNPs according to your project objectives.
We connect ionizable lipid structure, helper lipid balance, cholesterol content, and PEG-lipid architecture with cardiac delivery outcomes. This structure-guided approach helps investigate formulation variables that may influence myocardial exposure rather than relying on conventional liver-oriented LNP compositions.

Our development workflows cover cardiac-homing peptide synthesis, lipid-anchor conjugation, surface display, and ligand-density optimization. We evaluate targeting components according to their experimental evidence, target accessibility, and compatibility with the selected LNP composition.
We consider intravenous, intracoronary, and intramyocardial administration when selecting lipid composition, surface architecture, and particle properties. Matching the formulation to the intended route helps address differences in circulation, myocardial exposure, tissue penetration, and local retention.
Particle profiling, cardiac-cell uptake, functional payload readouts, and tissue-distribution studies are combined in one development program. This allows formulation changes to be interpreted against both cellular and myocardial delivery data, including off-target organ exposure.
From lipid selection and ligand synthesis to nanoparticle assembly, characterization, and delivery evaluation, the development chain is organized within one integrated plan. Parallel candidate comparisons help identify the formulation variables that require further optimization.
Heart-targeted LNPs can be developed by modifying ionizable lipid structures, optimizing PEG-lipid composition, or introducing cardiac-homing ligands. These modifications influence protein adsorption, tissue distribution, cellular uptake, and intracellular payload release. Other approaches include acid-responsive lipid components and formulation-process optimization to improve myocardial delivery. The optimal design depends on the target cardiac cell population, payload characteristics, and administration route. BOC Sciences supports customized ionizable lipid screening, targeting ligand synthesis, surface functionalization, and LNP formulation to develop cardiac-directed delivery systems.
Cardiomyocyte delivery depends on several interconnected factors, including particle size, surface charge, lipid composition, PEG-lipid density, and interactions with circulating proteins. After systemic administration, hepatic accumulation can reduce the amount of LNPs reaching myocardial tissue. Vascular access, extracellular matrix barriers, cellular uptake, and endosomal escape further influence functional delivery. BOC Sciences evaluates these parameters through lipid composition screening, particle characterization, cardiomyocyte uptake studies, and tissue distribution analysis to identify formulation characteristics associated with improved cardiac delivery.
Yes. Heart-targeted LNPs can be designed for different payload classes, including mRNA, siRNA, plasmid DNA, microRNA, antisense oligonucleotides, and selected protein or small-molecule payloads. Applications include cardiac protein expression, gene silencing, genome-editing research, inflammatory pathway modulation, and myocardial repair studies. Each payload requires an appropriate loading strategy based on its molecular size, charge, structural stability, and intracellular destination. BOC Sciences provides payload-compatible LNP formulation, encapsulation optimization, and functional delivery evaluation for different cardiovascular research objectives.
Administration routes influence LNP circulation, cardiac exposure, tissue penetration, and local retention. Intravenous administration provides systemic exposure but may result in substantial hepatic accumulation. Intracoronary delivery introduces nanoparticles through the coronary circulation, while intramyocardial injection provides more localized exposure around the injection site. Each route presents different formulation and evaluation requirements. BOC Sciences considers the intended administration route when selecting lipid composition, particle properties, and surface modifications, helping researchers compare delivery strategies according to their target myocardial region and experimental objectives.
Evaluation combines physicochemical characterization, cardiac-cell uptake analysis, functional payload measurements, and tissue-level distribution studies. Particle size, polydispersity index, zeta potential, morphology, and encapsulation efficiency provide information about formulation properties. Cellular studies can compare uptake in cardiomyocytes, cardiac fibroblasts, and endothelial cells, while functional assays assess reporter expression, gene knockdown, or protein production. In vivo evaluation can examine myocardial accumulation, cardiac cell localization, and distribution in organs such as the liver and spleen. These complementary measurements help determine whether an LNP achieves meaningful cardiac delivery.